HOOKIPA Pharma

HOOKIPA Pharma Inc. (NASDAQ: HOOK) was founded in 2011, and is headquartered in New York City. They are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.